Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales
- Judge issues order after upholding jury verdict Amgen won
- Ban takes effect in 30 days to give Sanofi time to appeal
This article is for subscribers only.
Amgen Inc. won a court ruling blocking rivals Sanofi and Regeneron Pharmaceuticals Inc. from selling their cholesterol-lowering drug Praluent in the U.S. because it infringes Amgen’s patents covering a rival treatment.
U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron Thursday to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication. The order is a setback for the losing drugmakers since analysts expected Praluent to generate $2 billion in sales by 2020.